Bayer Corporation v. Union of India: India's first compulsory licence and the patient-perspective reading of Section 84

Bayer Corporation v. Union of India is the case in which India's compulsory-licence architecture moved from text to practice. Section 84 of the Patents Act 1970 had been on the statute book for more than four decades. The 2005 TRIPS-compliance amendments had recast its language. The administrative machinery — the Controller of Patents under Section 84, the Intellectual Property Appellate Board on appeal — had been in place since 2003. But until the Patent Controller P.H. Kurian's order of 9 March 2012 granting Natco Pharma a compulsory licence over Bayer's Indian patent on Sorafenib Tosylate, no compulsory licence had ever been granted in independent India. The order travelled through the IPAB, which affirmed the grant on 4 March 2013 with a royalty revision from 6 per cent to 7 per cent of Natco's net sales, and on to the Bombay High Court Division Bench presided over by Chief Justice Mohit S. Shah, sitting with M.S. Sanklecha, J., which delivered judgment on 15 July 2014. The Supreme Court dismissed Bayer's Special Leave Petition on 12 December 2014 in a brief order — refusing to interfere but leaving the questions of law open.

The judgment is reported at 2014 (60) PTC 277 (Bom). The reasoning is organised around the three grounds of Section 84(1), each treated as independently sufficient, and around a sustained engagement with the statutory text of the "worked in India" requirement and the patient-perspective reading of "reasonably affordable price". The doctrinal architecture established at Bombay has carried through the decade and shaped — through the Patent Office's subsequent rejection of the BDR Pharma application for Dasatinib (Sprycel) on 29 October 2013 and of the Lee Pharma application for Saxagliptin (Onglyza) on 19 January 2016 — the practical contours of Indian compulsory licensing in pharmaceuticals.

The statutory architecture

Section 84 of the Patents Act 1970, as recast in 2005, opens with a three-ground test in sub-section (1):

(1) At any time after the expiration of three years from the date of the grant of a patent, any person interested may make an application to the Controller for grant of compulsory licence on patent on any of the following grounds, namely — (a) that the reasonable requirements of the public with respect to the patented invention have not been satisfied, or (b) that the patented invention is not available to the public at a reasonably affordable price, or (c) that the patented invention is not worked in the territory of India.

The grounds are disjunctive. The Bombay Bench treated this as an important structural fact: each ground is independently sufficient; the Controller is not required to find all three; and where all three are made out, each is to be sustained on its own evidentiary record.

Sub-sections (6) and (7) supply the operative definitional content. Sub-section (6) lays down the factors the Controller is to take into account in determining the Section 84(1)(a) "reasonable requirements" question — including (i) the nature of the invention, (ii) the time elapsed since sealing, (iii) the measures already taken by the patentee to make full use of the invention, (iv) the applicant's ability to work the invention to the public advantage, (v) the applicant's capacity to undertake the risk, and (vi) whether the applicant has made efforts to obtain a licence from the patentee on reasonable terms and conditions. Sub-section (7) supplies a non-exhaustive deeming clause for "reasonable requirements not met" — covering refusal to grant licences on reasonable terms, prejudice to the trade or industry of India, demand not met to an adequate extent or on reasonable terms, market for export not supplied, and establishment or development of commercial activities in India prejudiced.

Section 90 governs the terms and conditions of the compulsory-licence grant — including royalty quantum, scope of use, duration and quality controls. Section 92A governs export-only licences for least-developed and developing countries with insufficient pharmaceutical manufacturing capacity (the Indian transposition of the post-Doha 30 August 2003 WTO General Council Decision on Implementation of Paragraph 6 of the Doha Declaration). Section 100 deals with Government-use authorisations under a separate framework.

The international architecture is set out at Article 31 of TRIPS — the floor for compulsory licensing — and the Doha Declaration on the TRIPS Agreement and Public Health 2001, which affirmed members' freedom to determine the grounds on which compulsory licences are granted and reaffirmed that TRIPS does not and should not prevent members from taking measures to protect public health. The Bombay judgment treats the Doha Declaration as the interpretive lens through which the post-2005 Section 84 is to be read.

The factual matrix

Bayer Corporation held Indian patent IN 215758, granted on 3 March 2008 with priority date 12 January 2000, on the API Sorafenib Tosylate. The molecule is a tyrosine-kinase inhibitor used in the treatment of advanced renal-cell carcinoma (kidney cancer) and hepatocellular carcinoma (liver cancer). Bayer marketed it internationally — and in India after 2008 — as Nexavar.

Bayer's Indian distribution was modest. The drug was priced at approximately ₹2.8 lakh per month for a standard 120-tablet course. The Indian patient population requiring the drug had been estimated, on the basis of population-incidence data for advanced renal and hepatic cancers, at around 8,842 patients per year for the kidney-cancer indication alone; the figure for liver cancer was substantially higher. Bayer's import and supply figures, drawn from the customs and the Department of Pharmaceuticals records and reproduced in the IPAB order, showed total supply of fewer than 200 packs across 2008–2011 — a coverage rate well below 5 per cent of the relevant patient population on any plausible accounting.

Cipla Ltd, an Indian generic manufacturer not party to the compulsory-licence proceedings, had begun marketing a parallel generic version of Sorafenib in India in 2010 at approximately ₹28,000 per month. Bayer had instituted infringement proceedings against Cipla in the Delhi High Court. Those proceedings were live at the time of the Natco compulsory-licence application but were not finally decided in Bayer's favour.

Natco Pharma applied for a compulsory licence on 29 July 2011, after the expiration of the three-year period from grant of IN 215758. Natco's application asserted all three grounds of Section 84(1) and offered to supply the drug at approximately ₹8,800 per month — a 97 per cent reduction from Bayer's price. The Controller, P.H. Kurian, after hearings, granted the compulsory licence on 9 March 2012 with terms set under Section 90: a royalty of 6 per cent of Natco's net sales, supply to all patients in need on a non-discriminatory basis, free supply to at least 600 needy patients per year, and quality controls.

Bayer's appeal to the IPAB was decided on 4 March 2013. The IPAB affirmed the Controller's findings on each of the three Section 84(1) grounds. The IPAB modified the royalty from 6 per cent to 7 per cent to reflect what it considered a more appropriate balancing of patentee return and affordability, and otherwise preserved the terms. Bayer carried the matter to the Bombay High Court by writ petition.

The Court's reasoning

The Bench's reasoning runs through the three statutory grounds in sequence, with extended treatment of the "reasonably affordable price" and "worked in India" questions, and an institutional discussion of the standard of review on a writ petition against a specialised-tribunal order.

Standard of review

A preliminary question concerned the scope of review. Bayer pressed for a substantive re-examination of the IPAB's findings. The Bench held the writ jurisdiction does not extend to a merits re-trial. The IPAB is a specialised tribunal with statutory composition (a technical member and a judicial member) and the Controller is an expert administrative authority. Where the findings are supported by evidence and the legal construction is defensible, the High Court does not substitute its view for the tribunal's. The judgment is, accordingly, structured as an exercise in confirming the rationality and the legality of the IPAB's reasoning, not as a re-decision of the compulsory-licence application.

Section 84(1)(a) — reasonable requirements of the public unmet

The first ground required an assessment of whether Bayer had supplied Nexavar in quantities sufficient to meet the patient population's reasonable requirements. Bayer's defence ran on two arguments: that the patient-need figure should be heavily discounted because not all indicated patients would clinically receive Sorafenib; and that Cipla's parallel generic supply at ₹28,000 per month should be aggregated with Bayer's own to assess whether reasonable requirements were being met. The Bench held the discount argument, even on the most aggressive counting, did not rescue Bayer's supply ratio. The aggregation argument was rejected categorically: an "infringer's" supply cannot, under the patent-architecture of the 1970 Act, discharge the patentee's Section 84 obligation.

Section 84(1)(b) — price not reasonably affordable

The interpretive question was whose perspective the assessment is conducted from. Bayer pressed a patentee-perspective construction — that "reasonably affordable" must be read by reference to research-and-development costs, regulatory costs and risk-adjusted return on capital. The Bench rejected the construction. Section 84(1)(b) sits in the chapter on compulsory licensing; its statutory purpose is access; its placement in the post-TRIPS public-health framework — read through the Doha Declaration's affirmation of members' freedom to determine compulsory-licence grounds in protection of public health — required a patient-and-public-perspective reading. Applied to the record, Bayer's ₹2.8 lakh per month, set against per-capita-income indicators and against Natco's ₹8,800 offer, was plainly not reasonably affordable. The IPAB's finding was upheld.

Section 84(1)(c) — patent not worked in India

The third ground was, in some ways, the most doctrinally consequential. Bayer's defence was that "worked in India" can be satisfied by importation. The Bench did not lay down a flat rule that importation never constitutes working — importation in commercially significant quantities may suffice. But importation alone, in commercially insignificant quantities, does not. The Bench drew on the Form 27 annual-statement architecture under Section 146(2) and on the Section 83 general principles (patents granted to secure inventions are worked in India on a commercial scale to the fullest extent reasonably practicable). The statutory ecology contemplates manufacture in India or, where importation is the route, importation in commercially significant quantities. Bayer's fewer than 200 packs across 2008–2011 was insufficient on any view.

The royalty quantum and the institutional posture

The 6 per cent royalty fixed by the Controller and revised to 7 per cent by the IPAB was not disturbed — a matter for the specialised tribunal's expert judgment within the band of reasonableness contemplated by Section 90, with UNDP-WIPO and WHO benchmarks (4–6 per cent for middle-income economies) noted as comparative reference; the 7 per cent figure was at the upper end of the band but not unreasonable.

The doctrinal contribution

Bayer Corporation contributes to Indian patent law on four axes. The patient-perspective reading of "reasonably affordable price" supplies the operative interpretive frame for Section 84(1)(b) — the affordability question is conducted from the patient and public side; the patentee's cost-recovery and return concerns are not the criterion. The "worked in India" gloss establishes that importation alone, in commercially insignificant quantities, does not satisfy Section 84(1)(c) — a text-and-policy reading anchored in Section 83 and the Form 27 architecture. The three-ground disjunctive architecture treats each of the three Section 84(1) grounds as independently sufficient on its own evidentiary record. And the institutional posture on writ review of IPAB orders establishes a deferential standard — the High Court does not substitute its view where the findings are supported by evidence and the legal construction is defensible. The posture has shaped subsequent writ-review of IPAB and (after its abolition by the Tribunals Reforms Act 2021) High Court patent-bench orders.

What the judgment did not decide

The Bench did not address the export-only compulsory licence architecture under Section 92A — the Indian transposition of the post-Doha Paragraph-6 mechanism remains untested in litigation. It did not address the interaction of compulsory licensing with infringement proceedings: Bayer's pending Delhi action against Cipla was noted but not engaged. It did not lay down a general numerical threshold for what level of importation suffices to constitute working in India; the construction is fact-sensitive. And the Supreme Court's SLP-dismissal order of 12 December 2014 expressly left the questions of law open — the Bombay reasoning has in subsequent practice been treated as authoritative but has not yet been Supreme-Court-endorsed.

The doctrinal arc — the Bayer-BDR-Lee trilogy

The Bayer line has had a short and instructive sequel.

BDR Pharma's application for Dasatinib. Within months of the Natco grant, BDR Pharma Pvt Ltd applied for a compulsory licence over Bristol-Myers Squibb's Indian patent on Dasatinib — the molecule marketed as Sprycel in chronic myeloid leukaemia. The Controller, by an order of 29 October 2013, rejected the application at the threshold under Section 84(6)(iv) — failure to make a prima facie case that the applicant had made efforts to obtain a voluntary licence on reasonable terms. The correspondence with Bristol-Myers Squibb was held insufficiently serious and insufficiently pursued. A note on accuracy: the BDR Pharma application was for Dasatinib, not for Trastuzumab; the two are distinct.

Lee Pharma's application for Saxagliptin. Lee Pharma Ltd applied in 2015 for a compulsory licence over AstraZeneca's Indian patent on Saxagliptin — the DPP-4 inhibitor marketed as Onglyza for type-2 diabetes. The Controller, by an order of 19 January 2016, rejected at the prima facie stage on all three Section 84(1) grounds — patient need not unmet (other DPP-4 inhibitors available), affordability not established, working-in-India not made out.

The result. One grant (Natco) followed by two rejections has, in practice, frozen the Indian compulsory-licence pipeline. No further compulsory licence has been granted in the decade since. The Bayer doctrine remains operative but is applied with caution: applicants must discharge the Section 84(6)(iv) negotiation burden with documentary rigour, and patient-need, affordability and working questions are assessed strictly on the molecule's market and the applicant's record.

What practitioners take

For the applicant. The application should be structured around all three Section 84(1) grounds, each with its own evidentiary record. Patient-need evidence — incidence and prevalence data, treatment-uptake estimates, supply figures — should be tendered with primary-source provenance. Affordability evidence should be assembled from the patient-and-public perspective with comparator generic pricing. Working-in-India evidence should include the patentee's Form 27 statements. The voluntary-licence-negotiation record under Section 84(6)(iv) must be documented with precision — letters with reasonable terms, sufficient time for response, follow-up correspondence — to clear the BDR Pharma threshold.

For the patentee defending. The defence should engage each ground separately. The patient-need engagement should attack population-base assumptions and supply-coverage counting. The affordability engagement should — recognising the patentee-perspective argument failed in Bayer — focus on patient-assistance programmes, public-private supply and government-funded routes. The working engagement should marshal manufacturing-in-India arrangements (where available) and, where importation is the route, demonstrate commercially significant volumes calibrated to the patient population.

For upstream drafting. The compulsory-licence risk informs the upstream strategy. Voluntary-licence arrangements with Indian generic manufacturers — pioneered by Gilead for HIV antiretrovirals — operate as structural insurance against Section 84 exposure.

For TRIPS-and-policy. The reading of Section 84 through the Doha Declaration's lens — affirming members' freedom to determine compulsory-licence grounds in protection of public health — is settled in Indian jurisprudence.

The doctrinal residue

Bayer Corporation is the foundational Indian authority on compulsory licensing. The three-ground disjunctive architecture, the patient-perspective reading of "reasonably affordable price", the gloss on "worked in India" and the deferential writ-review posture have together defined the working framework. Read with Novartis — which closes the patentability gate against incremental-pharma claims at the front end — and with the post-grant patent-defence architecture worked out in F. Hoffmann-La Roche v. Cipla, the Bayer judgment supplies the post-grant access-instrument of Indian pharmaceutical patent law. The Bayer-BDR-Lee trilogy, considered as a whole, defines what the doctrine has produced in practice — a robust theoretical architecture, applied with operational caution, and now ten years without a further grant.

Related editorial pieces

• Novartis AG v. Union of India: the enhanced-therapeutic-efficacy gloss on Section 3(d)
• F. Hoffmann-La Roche v. Cipla: the s.3(d) eligibility / defence distinction and the Tarceva framework
• Delhi HC in CMYK Printech: the trademark-copyright interface in printing-and-publishing trade dress
• Delhi HC in Hindware v. Google Ads: keyword-bidding, trademark infringement and intermediary liability